FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1581736236> ?p ?o ?g. }

• W1581736236 abstract "Background: In pts with ESBC, cryo combined with cytotoxic T-lymphocyte antigen 4 blockade was well tolerated and did not delay standard-of-care mastectomy. As observed in mice, cryo+ipi may liberate tumor-associated antigens, synergistically activate tumor-reactive T-cells, and confer long-term anti-tumor immunity. Because singular biomarkers of response to immunotherapy have not been well defined, we conducted an integrated immunologic assessment to explore potential predictors of immune activation and response. Methods: Serial blood and pre-/post-treatment tumor tissue were collected from 18 pts treated with cryo (6 pts), single-dose ipi at 10mg/kg (6 pts), or cryo + ipi (6 pts). A Meso Scale Discovery platform was used to measure plasma cytokine interferon gamma (IFNγ). Multiparameter flow cytometry was used to evaluate peripheral and intratumoral T-cell and myeloid cell quantity, T-cell phenotype (effector versus regulatory), proliferation state (Ki67), and activation state (inducible costimulator [ICOS] expression). Finally, a DNA deep sequencing platform was used to conduct T-cell repertoire analysis of peripheral T-cells and TILs. Results: Sustained >2-fold elevations (1 month post-treatment) in plasma IFNγ were observed in the majority (4/6) of pts receiving cryo/ipi (median 6-fold increase), but in the minority of pts receiving cryo (0/6, median 0-fold) or ipi (2/6, median 0-fold). Similarly, sustained >2 fold elevations in ICOS expression in peripheral CD3+CD4+ T-cells, a known pharmacodynamic marker of ipi, were observed in the majority (5/6) of pts receiving cryo/ipi (median 4-fold increase), but in the minority of pts receiving cryo (0/6, median 0-fold) or ipi (2/6 ipi; median 1-fold). No trends were observed in peripheral myeloid derived suppressor cells. Analysis of TILs by flow cytometry identified increased numbers of proliferating CD8+ T-cells (CD8+Ki67+) in ipi and cryo/ipi groups relative to cryo alone; furthermore, the ratio of proliferating (CD8+Ki67+) to regulatory (CD4+CD25+FoxP3+) cells was enhanced in the cryo/ipi group. Finally, analysis of T-cell repertoire in TILs demonstrated that cryo/ipi generated an influx of novel T-cell clones, with select clones surging dramatically in predominance and circulating within the periphery. Conclusions: Utilizing an integrated assessment, we identified evidence of immunologic synergy with combination cryo/ipi versus either therapy alone. Of the tested parameters, peripheral CD4+ ICOS expression, plasma IFNγ, Ki67-gated TIL effector/regulatory ratios, and clonal repertoire analysis were identified as promising biomarkers of immune activation. These findings will inform a prospective assessment of potential immunologic biomarkers of immune response and clinical benefit in a phase 2 study of cryo-immunotherapy in ESBC. Citation Format: David Page, Jianda Yuan, Adi Diab, Zhiwan Dong, Arielle Ginsberg, Phillip Wong, Ryan Emerson, David Redmond, Brian Blum, Zhenyu Mu, Chunjun Zhao, Christopher Comstock, Elizabeth Morris, Elizabeth Comen, Alan Kotin, Janice Sung, Edi Brogi, Monica Morrow, Stephen Solomon, Virgilio Sacchini, Majid Maybody, Deirdre Neville, Harlan Robins, Sujata Patil, Jedd Wolchok, Clifford Hudis, Larry Norton, James Allison, Padmanee Sharma, Heather McArthur. Integrated immunologic assessment of tumor infiltrating lymphocytes (TILs) and peripheral blood to assess synergy of cryoablation (cryo) plus ipilimumab (ipi) in early stage breast cancer (ESBC) patients (pts) [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P2-15-01." @default.
• W1581736236 created "2016-06-24" @default.
• W1581736236 creator A5000824285 @default.
• W1581736236 creator A5007002927 @default.
• W1581736236 creator A5009038938 @default.
• W1581736236 creator A5015970952 @default.
• W1581736236 creator A5016923887 @default.
• W1581736236 creator A5017531113 @default.
• W1581736236 creator A5021783178 @default.
• W1581736236 creator A5024574591 @default.
• W1581736236 creator A5029855909 @default.
• W1581736236 creator A5030513928 @default.
• W1581736236 creator A5030834372 @default.
• W1581736236 creator A5039225060 @default.
• W1581736236 creator A5040821779 @default.
• W1581736236 creator A5043614486 @default.
• W1581736236 creator A5047117233 @default.
• W1581736236 creator A5047713528 @default.
• W1581736236 creator A5054656505 @default.
• W1581736236 creator A5057435796 @default.
• W1581736236 creator A5060626660 @default.
• W1581736236 creator A5060849697 @default.
• W1581736236 creator A5069656105 @default.
• W1581736236 creator A5071033599 @default.
• W1581736236 creator A5075052548 @default.
• W1581736236 creator A5075531820 @default.
• W1581736236 creator A5076836211 @default.
• W1581736236 creator A5080183722 @default.
• W1581736236 creator A5082985416 @default.
• W1581736236 creator A5086912994 @default.
• W1581736236 creator A5088301461 @default.
• W1581736236 creator A5090365102 @default.
• W1581736236 date "2015-04-30" @default.
• W1581736236 modified "2023-09-30" @default.
• W1581736236 title "Abstract P2-15-01: Integrated immunologic assessment of tumor infiltrating lymphocytes (TILs) and peripheral blood to assess synergy of cryoablation (cryo) plus ipilimumab (ipi) in early stage breast cancer (ESBC) patients (pts)" @default.
• W1581736236 doi "https://doi.org/10.1158/1538-7445.sabcs14-p2-15-01" @default.
• W1581736236 hasPublicationYear "2015" @default.
• W1581736236 type Work @default.
• W1581736236 sameAs 1581736236 @default.
• W1581736236 citedByCount "1" @default.
• W1581736236 countsByYear W15817362362017 @default.
• W1581736236 crossrefType "proceedings-article" @default.
• W1581736236 hasAuthorship W1581736236A5000824285 @default.
• W1581736236 hasAuthorship W1581736236A5007002927 @default.
• W1581736236 hasAuthorship W1581736236A5009038938 @default.
• W1581736236 hasAuthorship W1581736236A5015970952 @default.
• W1581736236 hasAuthorship W1581736236A5016923887 @default.
• W1581736236 hasAuthorship W1581736236A5017531113 @default.
• W1581736236 hasAuthorship W1581736236A5021783178 @default.
• W1581736236 hasAuthorship W1581736236A5024574591 @default.
• W1581736236 hasAuthorship W1581736236A5029855909 @default.
• W1581736236 hasAuthorship W1581736236A5030513928 @default.
• W1581736236 hasAuthorship W1581736236A5030834372 @default.
• W1581736236 hasAuthorship W1581736236A5039225060 @default.
• W1581736236 hasAuthorship W1581736236A5040821779 @default.
• W1581736236 hasAuthorship W1581736236A5043614486 @default.
• W1581736236 hasAuthorship W1581736236A5047117233 @default.
• W1581736236 hasAuthorship W1581736236A5047713528 @default.
• W1581736236 hasAuthorship W1581736236A5054656505 @default.
• W1581736236 hasAuthorship W1581736236A5057435796 @default.
• W1581736236 hasAuthorship W1581736236A5060626660 @default.
• W1581736236 hasAuthorship W1581736236A5060849697 @default.
• W1581736236 hasAuthorship W1581736236A5069656105 @default.
• W1581736236 hasAuthorship W1581736236A5071033599 @default.
• W1581736236 hasAuthorship W1581736236A5075052548 @default.
• W1581736236 hasAuthorship W1581736236A5075531820 @default.
• W1581736236 hasAuthorship W1581736236A5076836211 @default.
• W1581736236 hasAuthorship W1581736236A5080183722 @default.
• W1581736236 hasAuthorship W1581736236A5082985416 @default.
• W1581736236 hasAuthorship W1581736236A5086912994 @default.
• W1581736236 hasAuthorship W1581736236A5088301461 @default.
• W1581736236 hasAuthorship W1581736236A5090365102 @default.
• W1581736236 hasConcept C121608353 @default.
• W1581736236 hasConcept C126322002 @default.
• W1581736236 hasConcept C143998085 @default.
• W1581736236 hasConcept C147483822 @default.
• W1581736236 hasConcept C203014093 @default.
• W1581736236 hasConcept C2776090121 @default.
• W1581736236 hasConcept C2777701055 @default.
• W1581736236 hasConcept C2778326572 @default.
• W1581736236 hasConcept C2781433595 @default.
• W1581736236 hasConcept C530470458 @default.
• W1581736236 hasConcept C71924100 @default.
• W1581736236 hasConcept C8891405 @default.
• W1581736236 hasConceptScore W1581736236C121608353 @default.
• W1581736236 hasConceptScore W1581736236C126322002 @default.
• W1581736236 hasConceptScore W1581736236C143998085 @default.
• W1581736236 hasConceptScore W1581736236C147483822 @default.
• W1581736236 hasConceptScore W1581736236C203014093 @default.
• W1581736236 hasConceptScore W1581736236C2776090121 @default.
• W1581736236 hasConceptScore W1581736236C2777701055 @default.
• W1581736236 hasConceptScore W1581736236C2778326572 @default.
• W1581736236 hasConceptScore W1581736236C2781433595 @default.
• W1581736236 hasConceptScore W1581736236C530470458 @default.
• W1581736236 hasConceptScore W1581736236C71924100 @default.
• W1581736236 hasConceptScore W1581736236C8891405 @default.
• W1581736236 hasLocation W15817362361 @default.
• W1581736236 hasOpenAccess W1581736236 @default.
• W1581736236 hasPrimaryLocation W15817362361 @default.
• W1581736236 hasRelatedWork W1215790105 @default.

• next